General Statement of Disclosure:

CONSULTING FEES/HONORARIA: PlaqueTec(NONE) RESEARCH/RESEARCH GRANTS: Novartis(SIGNIFICANT) OTHER FINANCIAL BENEFIT: Amgen(NONE), AstraZeneca Pharmaceuticals(NONE), Esperion Therapeutics(NONE), Kowa Pharmaceuticals(NONE), Novartis(NONE), Pfizer(NONE), Sanofi-Regeneron(NONE), MedImmune, Inc(NONE), Amgen Inc.(NONE), Beren Therapeutics(NONE), Baim Institute(NONE), Genentech(NONE), Kancera(NONE), Merck & Co., Inc.(NONE), Novo Nordisk Inc.(NONE), DalCor Pharmaceuticals(MODEST), Novartis Corporation(NONE), Olatec Therapeutics(NONE), Medimmune(NONE), Cartesian Therapeutics(NONE), Caristo Diagnostics(NONE), CSL Behring(NONE), Dewpoint Therapeutics(NONE), TenSixteen Bio(NONE), Moderna(NONE), Soley Therapeutics(NONE), TenSixteen Bio(NONE), XBiotech, Inc., TenSixteen Bio, Soley Therapeutics(NONE), Soley Therapeutics(NONE), XBioTech Inc(NONE), Eulicid Bioimaging(NONE)

View Full Disclosure